Molly Catherine Hardebeck

1.3k total citations · 1 hit paper
13 papers, 912 citations indexed

About

Molly Catherine Hardebeck is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Molly Catherine Hardebeck has authored 13 papers receiving a total of 912 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Molly Catherine Hardebeck's work include Advanced Breast Cancer Therapies (9 papers), Cancer-related Molecular Pathways (7 papers) and HER2/EGFR in Cancer Research (4 papers). Molly Catherine Hardebeck is often cited by papers focused on Advanced Breast Cancer Therapies (9 papers), Cancer-related Molecular Pathways (7 papers) and HER2/EGFR in Cancer Research (4 papers). Molly Catherine Hardebeck collaborates with scholars based in United States, Spain and Japan. Molly Catherine Hardebeck's co-authors include Miguel Martín, Matthew P. Goetz, Stephen Johnston, Martin Frenzel, Masakazu Toi, Bipasha Mukherjee, Nozomi Tomimatsu, Angelo Di Leo, Sandeep Burma and Hiroji Iwata and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Molly Catherine Hardebeck

13 papers receiving 899 citations

Hit Papers

MONARCH 3 final PFS: a randomized study of abemaciclib as... 2019 2026 2021 2023 2019 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
    2019 407 citations Stephen Johnston, Miguel Martín et al. npj Breast Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Molly Catherine Hardebeck United States 9 554 543 327 271 194 13 912
Martina Bonechi Italy 14 448 0.8× 463 0.9× 136 0.4× 207 0.8× 165 0.9× 20 602
Jens Enoksson Sweden 6 353 0.6× 246 0.5× 532 1.6× 176 0.6× 142 0.7× 8 763
Zhanfang Guo United States 11 335 0.6× 200 0.4× 351 1.1× 154 0.6× 63 0.3× 19 585
Jessica Sohl United States 8 607 1.1× 447 0.8× 133 0.4× 287 1.1× 119 0.6× 17 819
Paris Vail United States 14 506 0.9× 239 0.4× 260 0.8× 203 0.7× 50 0.3× 15 739
Jiangang Liu China 11 261 0.5× 212 0.4× 321 1.0× 186 0.7× 55 0.3× 29 628
Jorge Franco United States 7 372 0.7× 240 0.4× 183 0.6× 133 0.5× 67 0.3× 8 533
Gilad W. Vainer Israel 14 257 0.5× 213 0.4× 297 0.9× 245 0.9× 82 0.4× 28 700
Lili T. Belcastro United States 4 258 0.5× 195 0.4× 336 1.0× 149 0.5× 43 0.2× 8 576
A. Cseh Austria 12 393 0.7× 401 0.7× 176 0.5× 163 0.6× 128 0.7× 39 604

Countries citing papers authored by Molly Catherine Hardebeck

Since Specialization
Citations

This map shows the geographic impact of Molly Catherine Hardebeck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Molly Catherine Hardebeck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Molly Catherine Hardebeck more than expected).

Fields of papers citing papers by Molly Catherine Hardebeck

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Molly Catherine Hardebeck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Molly Catherine Hardebeck. The network helps show where Molly Catherine Hardebeck may publish in the future.

Co-authorship network of co-authors of Molly Catherine Hardebeck

This figure shows the co-authorship network connecting the top 25 collaborators of Molly Catherine Hardebeck. A scholar is included among the top collaborators of Molly Catherine Hardebeck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Molly Catherine Hardebeck. Molly Catherine Hardebeck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Lassaletta, Álvaro, Lucas Moreno, Chitose Ogawa, et al.. (2023). Recommended phase 2 dose (RP2D) for abemaciclib in combination with irinotecan (IRN) and temozolomide (TMZ) in pediatric patients with relapsed/refractory solid tumors (JPCS Part A).. Journal of Clinical Oncology. 41(16_suppl). 10039–10039. 1 indexed citations
2.
Johnston, Stephen, Joyce O’Shaughnessy, Miguel Martín, et al.. (2021). Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups. npj Breast Cancer. 7(1). 80–80. 36 indexed citations
3.
Toi, Masakazu, Kenichi Inoue, Norikazu Masuda, et al.. (2021). Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2− advanced breast cancer: MONARCH 2 & 3 trials. Cancer Science. 112(6). 2381–2392. 16 indexed citations
4.
Yee, Douglas, Patricia LoRusso, Aleix Prat, et al.. (2021). A phase Ib study of xentuzumab plus abemaciclib and fulvestrant in patients (pts) with advanced hormone receptor-positive (HR+), HER2-negative breast cancer (BC) with visceral or non-visceral disease.. Journal of Clinical Oncology. 39(15_suppl). 1057–1057. 1 indexed citations
5.
Hamilton, Erika, Javier Cortés, Özgür Özyılkan, et al.. (2020). nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer. Clinical Breast Cancer. 21(3). 181–190.e2. 29 indexed citations
6.
Yee, Douglas, Mafalda Oliveira, Hiroji Iwata, et al.. (2020). Abstract P3-11-05: A phase Ib multi-cohort study of xentuzumab and abemaciclib in patients (pts) with solid tumors and breast cancer (BC) - Initial report of four dose-finding cohorts. Cancer Research. 80(4_Supplement). P3–11. 1 indexed citations
7.
Johnston, Stephen, Miguel Martín, Angelo Di Leo, et al.. (2019). MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. npj Breast Cancer. 5(1). 5–5. 407 indexed citations breakdown →
8.
Martín, Miguel, Stephen Johnston, Jens Huober, et al.. (2019). MONARCH 3: Updated time to chemotherapy and disease progression following abemaciclib plus aromatase inhibitor (AI) in HR+, HER2- advanced breast cancer (ABC). Annals of Oncology. 30. v113–v114. 6 indexed citations
9.
Leo, Angelo Di, Joyce O’Shaughnessy, George W. Sledge, et al.. (2018). Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy. npj Breast Cancer. 4(1). 41–41. 48 indexed citations
10.
Tomimatsu, Nozomi, Bipasha Mukherjee, Janelle L. Harris, et al.. (2017). DNA-damage-induced degradation of EXO1 exonuclease limits DNA end resection to ensure accurate DNA repair. Journal of Biological Chemistry. 292(26). 10779–10790. 61 indexed citations
11.
Tomimatsu, Nozomi, Bipasha Mukherjee, Molly Catherine Hardebeck, et al.. (2014). Phosphorylation of EXO1 by CDKs 1 and 2 regulates DNA end resection and repair pathway choice. Nature Communications. 5(1). 3561–3561. 147 indexed citations
12.
Camacho, Cristel V., Molly Catherine Hardebeck, Nozomi Tomimatsu, et al.. (2014). DNA double-strand breaks cooperate with loss of Ink4 and Arf tumor suppressors to generate glioblastomas with frequent Met amplification. Oncogene. 34(8). 1064–1072. 22 indexed citations
13.
Alcazar, Carlos R. Gil Del, Molly Catherine Hardebeck, Bipasha Mukherjee, et al.. (2013). Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma. Clinical Cancer Research. 20(5). 1235–1248. 137 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martina Bonechi Breakdown of academic impact, for papers by Jens Enoksson Breakdown of academic impact, for papers by Zhanfang Guo Breakdown of academic impact, for papers by Jessica Sohl Breakdown of academic impact, for papers by Paris Vail Breakdown of academic impact, for papers by Jiangang Liu Breakdown of academic impact, for papers by Jorge Franco Breakdown of academic impact, for papers by Gilad W. Vainer Breakdown of academic impact, for papers by Lili T. Belcastro Breakdown of academic impact, for papers by A. Cseh
Rankless by CCL
2026